Amerise Biosciences Ltd

Transaction details

• Target: Amerise Biosciences Ltd.
• Acquirer and PACs: SNEHJEEV VENTURES PVT.LTD.; Rushank S. Lunkad; Sneha Lunkad; Riddhi Lunkad; Sanjeev Lunkad.
• Promoter group: No.
• Transaction: Acquisition of voting shares.
• Pre-holding: 7,215,959 shares (10.92%).
• Encumbrances before: Nil.
• Shares acquired: 76,725 shares (0.12%).
• Post-holding: 7,292,684 shares (11.04%).
• Mode: Open Market.
• Date: 14-08-2026.
• Equity capital before: Rs 6,60,69,000; shares: 66,06,900.
• Equity capital after: Rs 6,60,69,000; shares: 66,06,900.
• Total diluted capital after: NA.

Key filing details

• Target Company: Amerise Biosciences Ltd (AMERISE, 531681).
• Scrip/ID: AMERISE, 531681.
• Filing date: 29.07.2026.
• Disclosing Party: not disclosed in this chunk.
• Transaction Type: not disclosed.
• Pre-Transaction Holding: not disclosed.
• Transaction Details: not disclosed.
• Post-Transaction Holding: not disclosed.
• Date(s) of Transaction: not disclosed.
• Share Capital Context: not disclosed.

Filing summary

• Disclosure submission under Reg. 29(2) by Amerise Biosciences Ltd (Scrip 531681) dated 16 July 2026.

Dematerialisation status

• The dematerialised securities have been listed on the stock exchanges.
• Physical certificates were mutilated and cancelled; depository registered owner name substituted.
• No physical certificates were received for demat in the quarter.

Financial Performance 📊

• Total income was Rs 17.60 lacs for nine months ended Dec 31, 2025, down from Rs 18.80 lacs year ago.
• Total expenses rose to Rs 21.67 lacs for nine months, up from Rs 18.04 lacs year ago.
• Employee benefit expenses decreased to Rs 5.92 lacs from Rs 10.19 lacs year ago.
• Other expenses increased to Rs 15.75 lacs from Rs 7.86 lacs year ago.
• Loss before and after tax was Rs 4.07 lacs for nine months, compared to profit of Rs 0.76 lacs and Rs 0.57 lacs year ago.
• Basic and diluted EPS was negative Rs 0.01 per share for nine months (face value Rs 1).

Corporate Actions & Governance 📍

• Mr. Albert Hines appointed Whole-time Director and CFO effective Feb 2, 2026.
• Mr. Dinesh Rathod resigned as Whole-time Director and CFO effective Feb 2, 2026.

Audit & Compliance 🗒️

• Statutory auditors conducted limited review of unaudited financial results with no qualifications.

Business Model & Segments

• Company operates in a single segment; no segment-wise results disclosed.